Regeneron at ACT 2026
Nov 15–18, 2026 San Antonio, TX ~1.4k attendees Website
Regeneron takes part in 2 sessions at ACT 2026 in San Antonio. Its program centres on how drugs can affect hearing and balance during clinical development. It includes a case study of DB-OTO, a gene therapy delivered by an adeno-associated virus to treat auditory neuropathy caused by otoferlin gene variants.
| Organization | ACT 2026 Attendance |
|---|---|
Regeneron Tarrytown, NY | |
Biotech company that discovers, develops and markets antibody medicines and is building gene therapies, including for genetic hearing loss. | Session Wed Nov 18 9:00am–12:00pm Do You Hear What I Hear? Evaluating Otic and Vestibular Toxicity in Clinical Development (S14)
Talk Wed Nov 18 9:50am–10:15am |
Instantly find 20 buyers from Regeneron
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American College of Toxicology (ACT). Organization details are derived from ACT’s published program, exhibitor floor plan and supporter list, and each organization’s own website. Submit a correction